| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1846 | 2016 |
| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017 | 1231 | 2017 |
| A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee N Solish, V Bertucci, A Dansereau, HCH Hong, C Lynde, M Lupin, ... Dermatologic Surgery 33 (8), 908-923, 2007 | 536 | 2007 |
| Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double … E Guttman-Yassky, HD Teixeira, EL Simpson, KA Papp, AL Pangan, ... The Lancet 397 (10290), 2151-2168, 2021 | 404 | 2021 |
| Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial E Guttman-Yassky, D Thaçi, AL Pangan, HC Hong, KA Papp, K Reich, ... Journal of Allergy and Clinical Immunology 145 (3), 877-884, 2020 | 345 | 2020 |
| Dupilumab: a review of its use in the treatment of atopic dermatitis MJ Gooderham, HC Hong, P Eshtiaghi, KA Papp Journal of the American Academy of Dermatology 78 (3), S28-S36, 2018 | 324 | 2018 |
| Clinical evaluation of a microwave device for treating axillary hyperhidrosis H Chih‐Ho Hong, M Lupin, KF O'Shaughnessy Dermatologic Surgery 38 (5), 728-735, 2012 | 145 | 2012 |
| The temperamental characteristics of Chinese babies C Hsu, W Soong, JW Stigler, C Hong, C Liang Child Development, 1337-1340, 1981 | 142 | 1981 |
| Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical … EL Simpson, KA Papp, A Blauvelt, CY Chu, HC Hong, N Katoh, ... JAMA dermatology 158 (4), 404-413, 2022 | 140 | 2022 |
| Phase 3 trials of tapinarof cream for plaque psoriasis MG Lebwohl, L Stein Gold, B Strober, KA Papp, AW Armstrong, J Bagel, ... New England Journal of Medicine 385 (24), 2219-2229, 2021 | 139 | 2021 |
| A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized … A Blauvelt, K Papp, A Gottlieb, A Jarell, K Reich, C Maari, KB Gordon, ... British Journal of Dermatology 182 (6), 1348-1358, 2020 | 137 | 2020 |
| Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial K Reich, JP Thyssen, A Blauvelt, K Eyerich, W Soong, ZP Rice, HC Hong, ... The Lancet 400 (10348), 273-282, 2022 | 124 | 2022 |
| Efficacy and safety of topical WBI‐1001 in patients with mild to severe atopic dermatitis: results from a 12‐week, multicentre, randomized, placebo‐controlled double‐blind trial R Bissonnette, Y Poulin, Y Zhou, J Tan, HC Hong, J Webster, W Ip, L Tang, ... British Journal of Dermatology 166 (4), 853-860, 2012 | 99 | 2012 |
| Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies M De Bruin-Weller, T Biedermann, R Bissonnette, M Deleuran, P Foley, ... Acta Dermato-Venereologica 101 (2), 2021 | 88 | 2021 |
| Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL … CH Hong, KA Papp, KW Lophaven, P Skallerup, S Philipp Journal of the European Academy of Dermatology and Venereology 31 (11), 1876 …, 2017 | 61 | 2017 |
| Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial … EL Simpson, M Gooderham, A Wollenberg, S Weidinger, A Armstrong, ... JAMA dermatology 159 (2), 182-191, 2023 | 59 | 2023 |
| Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study LK Ferris, E Ott, J Jiang, HCH Hong, S Li, C Han, W Baran Journal of Dermatological Treatment 31 (2), 152-159, 2020 | 53 | 2020 |
| Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis MJ Gooderham, R Bissonnette, P Grewal, P Lansang, KA Papp, C Hong Journal of Cutaneous Medicine and Surgery 22 (1_suppl), 10S-16S, 2018 | 53 | 2018 |
| Review of systemic treatment options for adult atopic dermatitis M Gooderham, CW Lynde, K Papp, M Bourcier, L Guenther, W Gulliver, ... Journal of cutaneous medicine and surgery 21 (1), 31-39, 2017 | 53 | 2017 |
| Optimizing the use of topical brimonidine in rosacea management: panel recommendations. EA Tanghetti, JM Jackson, KT Belasco, A Friedrichs, F Hougier, ... Journal of Drugs in Dermatology: JDD 14 (1), 33-40, 2015 | 51 | 2015 |
